+

WO2003037930A1 - Nouveau polypeptide recepteur n-methyl-d-aspartate (nmda) du glutamate et gene codant pour celui-ci - Google Patents

Nouveau polypeptide recepteur n-methyl-d-aspartate (nmda) du glutamate et gene codant pour celui-ci Download PDF

Info

Publication number
WO2003037930A1
WO2003037930A1 PCT/JP2002/011207 JP0211207W WO03037930A1 WO 2003037930 A1 WO2003037930 A1 WO 2003037930A1 JP 0211207 W JP0211207 W JP 0211207W WO 03037930 A1 WO03037930 A1 WO 03037930A1
Authority
WO
WIPO (PCT)
Prior art keywords
nr3a
gene encoding
glutamate receptor
nmda
human
Prior art date
Application number
PCT/JP2002/011207
Other languages
English (en)
Japanese (ja)
Other versions
WO2003037930A8 (fr
Inventor
Hiroshi Mori
Osamu Ohara
Takahiro Nagase
Reiko Kikuno
Keiji Yamagami
Yoshitaka Ohashi
Original Assignee
Kazusa Dna Research Institute Foundation
Mitsubishi Pharma Corporation
Iritani, Shuji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kazusa Dna Research Institute Foundation, Mitsubishi Pharma Corporation, Iritani, Shuji filed Critical Kazusa Dna Research Institute Foundation
Priority to JP2003540211A priority Critical patent/JPWO2003037930A1/ja
Publication of WO2003037930A1 publication Critical patent/WO2003037930A1/fr
Publication of WO2003037930A8 publication Critical patent/WO2003037930A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)

Abstract

L'invention a pour objet la découverte d'un nouveau composant apparenté à la sous-unité 3A du récepteur NMDA (NR3A) humain du glutamate. Un nouvel ADNc trouvant son origine dans cerveau humain a été isolé et sa séquence de bases intégrale a été analysée. Cette séquence a ensuite été traduite en une séquence d'acides aminés, et cette étape a été suivie d'une recherche d'homologie. On a ainsi découvert que cette séquence présente 93 % d'homologie avec le NR3A du rat, ce qui a permis de l'identifier en tant que NT3A humain. Il a en outre été confirmé qu'un gène codant pour NR3A est présent en quantités sensiblement accrues dans le cerveau des patients atteints de schizophrénie, ce qui permet de conclure que le NR3A est un composant associé à la pathologie de la schizophrénie.
PCT/JP2002/011207 2001-10-29 2002-10-29 Nouveau polypeptide recepteur n-methyl-d-aspartate (nmda) du glutamate et gene codant pour celui-ci WO2003037930A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003540211A JPWO2003037930A1 (ja) 2001-10-29 2002-10-29 新規なヒトＮ−ｍｅｔｈｙｌ−Ｄ−ａｓｐａｒｔａｔｅ（ＮＭＤＡ）型グルタミン酸受容体ポリペプチドおよびそれをコードする遺伝子

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001331007 2001-10-29
JP2001-331007 2001-10-29
JP2001-333258 2001-10-30
JP2001333258 2001-10-30
JP2001345262 2001-11-09
JP2001-345262 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003037930A1 true WO2003037930A1 (fr) 2003-05-08
WO2003037930A8 WO2003037930A8 (fr) 2004-06-03

Family

ID=27347747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/011207 WO2003037930A1 (fr) 2001-10-29 2002-10-29 Nouveau polypeptide recepteur n-methyl-d-aspartate (nmda) du glutamate et gene codant pour celui-ci

Country Status (2)

Country Link
JP (1) JPWO2003037930A1 (fr)
WO (1) WO2003037930A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2001044473A2 (fr) * 1999-12-14 2001-06-21 Curagen Corporation Polypeptides et acides nucleiques codant pour ces polypeptides
WO2001081413A2 (fr) * 2000-04-27 2001-11-01 Pe Corporation (Ny) Proteines de transport humaines isolees, molecules d'acides nucleiques codant pour les proteines de transport humaines et utilisations associees
WO2002012340A2 (fr) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Transporteurs et canaux ioniques
WO2002024743A2 (fr) * 2000-09-19 2002-03-28 Millennium Pharmaceuticals, Inc. 55063, nouveau membre de la famille nmda humaine et ses applications
WO2002040538A2 (fr) * 2000-11-17 2002-05-23 Bayer Aktiengesellschaft Regulation du recepteur nmda humain

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2001044473A2 (fr) * 1999-12-14 2001-06-21 Curagen Corporation Polypeptides et acides nucleiques codant pour ces polypeptides
WO2001081413A2 (fr) * 2000-04-27 2001-11-01 Pe Corporation (Ny) Proteines de transport humaines isolees, molecules d'acides nucleiques codant pour les proteines de transport humaines et utilisations associees
WO2002012340A2 (fr) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Transporteurs et canaux ioniques
WO2002024743A2 (fr) * 2000-09-19 2002-03-28 Millennium Pharmaceuticals, Inc. 55063, nouveau membre de la famille nmda humaine et ses applications
WO2002040538A2 (fr) * 2000-11-17 2002-05-23 Bayer Aktiengesellschaft Regulation du recepteur nmda humain

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANDERSSON O. ET AL.: "Nucleotide sequence, genomic organization and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B", GENOMICS, vol. 78, no. 3, December 2001 (2001-12-01), pages 178 - 184, XP002962975 *
DAS S. ET AL.: "Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A", NATURE, vol. 393, no. 6683, 28 May 1998 (1998-05-28), pages 377 - 381, XP002962970 *
ERIKSSON M. ET AL.: "Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A", NEUROSCIENCE LETTERS, vol. 321, no. 3, 2002, pages 177 - 181, XP002962977 *
GOEBEL D.J. ET AL.: "NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A", MOL. BRAIN RES., vol. 69, no. 2, 8 June 1999 (1999-06-08), pages 164 - 170, XP002962971 *
PEREZ-OTANO I. ET AL.: "Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors", J. NEUROSCI., vol. 21, no. 4, 15 February 2001 (2001-02-15), pages 1228 - 1237, XP002962972 *
SASAKI Y.F. ET AL.: "Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons", J. NEUROPHYSIOL., vol. 87, no. 4, April 2002 (2002-04-01), pages 2052 - 2063, XP002962976 *
SUCHER N.J. ET AL.: "Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain", J. NEUROSCI., vol. 15, no. 10, October 1995 (1995-10-01), pages 6509 - 6520, XP001061256 *
TU S. ET AL.: "Generation of NR3A transgenic mice", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, pages 1850, XP002962974 *
VON EULER G. ET AL.: "Nucleotide sequence, genomic organization and chromosomal localization of the human NMDA receptor subunit NR3A", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, pages 920, XP002962973 *

Also Published As

Publication number Publication date
JPWO2003037930A1 (ja) 2005-02-17
WO2003037930A8 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
BR0207325A (pt) Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1
EP2298355A3 (fr) Protéines de fusion d'albumine
IS8622A (is) Aðferð til þess að búa til fjölpeptíðablöndur meðþví að nota hreinsaða brómvetnissýru
WO2005115306A3 (fr) Polypeptide liant la keratine
MXPA05002991A (es) Analogos de ghrh.
AU5608000A (en) 22025, a novel human cyclic nucleotide phosphodiesterase
WO2004080957A3 (fr) Utilisation de poylpeptides adnf pour traiter l'anxiete et la depression
WO2003075944A3 (fr) Molecules de type interferon beta destinees au traitement des accidents vasculaires cerebraux
EP0816504A3 (fr) Facteur d'activation des plaquettes acétylhydrolase, et gène codant celui-ci
WO2002004487A3 (fr) Procede d'extraction et d'utilisation de nouvelles defensines humaines en tant que proteines biologiquement actives pour traiter des infections et autres pathologies
WO2003037930A1 (fr) Nouveau polypeptide recepteur n-methyl-d-aspartate (nmda) du glutamate et gene codant pour celui-ci
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
HK1079549A1 (en) Muteins of placental growth factor type 1, preparation method and application thereof
WO2002102847A1 (fr) Nouveau ligand et son adn
AU5909600A (en) 17867, a novel human aminopeptidase
WO2003082897A3 (fr) Fragments de peptides actifs synthetiques
WO2002008424A1 (fr) Genes abca2 humain et de rat
WO2001090139A3 (fr) Ligand pour ameliorer l'administration d'agents biologiques par voie orale et via le systeme nerveux central
WO2004113511A3 (fr) Lignee cellulaire et ses utilisations
WO2001090141A3 (fr) Nouvelle isoforme gb1c et nucleotides codant pour celle-ci
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
WO2002016435A3 (fr) Proteines humaines 7tm et polynucleotides codant ces proteines
WO2001094417A3 (fr) Nouvelles proteines humaines a sept domaines transmembranaires et polynucleotides les codant
WO2002061083A1 (fr) Nouvelle proteine de recepteur couple aux proteines g et son adn
WO2002036633A3 (fr) Nouvelles proteines humaines 7tm et polynucleotides codant pour ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003540211

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2003 UNDER (72, 75) DELETE "IRITANI, SHUJI [JP/JP]; ROOM 110, ABITASHION-ROKAKOUEN, 11-25, KASUYA 2-CHOME, SETAGAYA-KU, TOKYO 157-0063"; UNDER (71) ADD "IRITANI, SHUJI [JP/JP]; ROOM 110, ABITASHION-ROKAKOUEN, 11-25, KASUYA 2-CHOME, SETAGAYA-KU, TOKYO 157-0063"

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载